热门资讯> 正文
Emergent Biotolions为CYFENDUS授予3000万美元的合同修改权
2025-09-02 20:08
- Emergent BioSolutions (NYSE:EBS) has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (OTCPK:ASPR) within the U.S. Department of Health and Human Services (HHS) to supply CYFENDUS.
- Deliveries are expected to begin this calendar year and are scheduled to be completed by March 2026.
- EBS +1.20% premarket to $8.4.
- Source: Press Release
More on Emergent Biosolutions
- Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally
- Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript
- Emergent BioSolutions: Strategic Turnaround Proving Tricky, But I'm Still Hopeful
- Emergent Biosolutions Q2 2025 Earnings Preview
- Emergent BioSolutions signs contract modification award for CNJ-016
推荐文章
港股周报丨降息周期重启！美联储如期降息25个基点；港股通年内净流入突破1万亿港元
美股机会日报 | 5.3万亿美元期权到期！美股“三巫日”今夜来袭；联邦快递盘前一度涨超5%
一周IPO丨三只新股齐上涨！健康160、劲方医药双双飙升至翻倍；奇瑞汽车、紫金黄金、西普尼火热招股中
一周财经日历 | 10月再降息25基点？美国8月PCE数据来袭；奇瑞汽车、紫金黄金等3只新股火热招股中
美股消费板块如何布局？瑞银首选清单出炉 百事(PEP.US)、Peloton(PTON.US)在列
电影《大空头》原型研判：美联储本轮降息周期短暂 AI仍是市场重头戏
英伟达与英特尔“世纪联手”引爆芯片产业链! 芯片背后的缔造者们拥抱“看涨狂潮”
新股申购 | 紫金黄金国际、西普尼两只新股今起招股
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
